CoChat
Sign Up
Cited by 225Seaweed-derived Bioactive CompoundsEchinoderm biology and ecologyFungal Biology and Applications

Therapies from Fucoidan: New Developments

Open access
Fitton, J. Helen, Stringer, Damien N., Park, Ah Young, Karpiniec, Samuel S.·2019·Marine Drugs
DOI 10.3390/md17100571PMC PMC6836154
Open this paper in CoChat — free accountOpen PDF

Abstract

Since our last review in 2015, the study and use of fucoidan has extended in several research areas. Clinical use of fucoidan for the treatment of renal disease has become available and human safety studies have been undertaken on radiolabeled fucoidan for the purpose of imaging thrombi. Fucoidan has been incorporated into an increasing number of commercially available supplements and topical treatments. In addition, new measuring techniques are now available to assess the biologically relevant uptake of fucoidans and to assist in production. Microbiome modulation and anti-pathogenic effects are increasingly promising applications for fucoidans, due to the need for alternative approaches to antibiotic use in the food chain. This review outlines promising new developments in fucoidan research, including potential future therapeutic use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/md17100571

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fucoidan-derived products have gained regulatory approval in several global jurisdictions; the FDA approved fucoidan extracts from U. pinnatifida and F. vesiculosus by Marinova as GRAS; the European Commission approved fucoidan extracts from the same species as a novel food; Canada and Australia approved numerous listed fucoidan-containing medicines; fucoidan was approved for oral consumption up,

    “Fucoidan-derived products have gained regulatory approval in several global jurisdictions. The United States Food and Drug Administration has approved fucoidan extracts from Undaria pinnatifida and F. vesiculosus by the Australian manufacturer Marinova as “Generally Recognized as Safe (GRAS)”. The European Commission approved fucoidan extracts from the same species as a novel food [101];”

    From A Review on Fucoidan Structure, Extraction Techniques, and Its Role as an Immunomodulatory Agent (2022) · cites this paper as [102]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 98 · Cited by 225

Research works printed but not linked: 93

  1. [1]Fitton J.H. Stringer D.N. Karpiniec S.S. Therapies from Fucoidan: An Update Mar. Drugs 2015 13 5920 5946 10.3390/md13095920 26389927 PMC4584361 · DOI · Paper page
  2. [2]Wang Y. Xing M. Cao Q. Ji A. Liang H. Song S. Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies Mar. Drugs 2019 17 183 10.3390/md17030183 30897733 PMC6471298 · DOI
  3. [3]Van Weelden G. Bobinski M. Okla K. van Weelden W.J. Romano A. Pijnenborg J.M.A. Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms Mar. Drugs 2019 17 32 10.3390/md17010032 30621045 PMC6356449 · DOI
  4. [4]Citkowska A. Szekalska M. Winnicka K. Possibilities of Fucoidan Utilization in the Development of Pharmaceutical Dosage Forms Mar. Drugs 2019 17 458 10.3390/md17080458 31387230 PMC6722496 · DOI
  5. [5]Wang J. Geng L. Yue Y. Zhang Q. Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies Prog. Mol. Biol. Transl. Sci. 2019 163 95 111 10.1016/bs.pmbts.2019.03.011 31030763 · DOI
  6. [6]Zheng K.H. Kaiser Y. Poel E. Verberne H. Aerts J. Rouzel F. Stroes E. Letourneur D. Chauvierre C. 99Mtc-Fucoidan As Diagnostic Agent For P-Selectin Imaging: First-In-Human Evaluation (Phase I) Atherosclerosis 2019 287 e143 10.1016/j.atherosclerosis.2019.06.425 · DOI
  7. [8]Charboneau A.J. Delaney J.P. Beilman G. Fucoidans inhibit the formation of post-operative abdominal adhesions in a rat model PLoS ONE 2018 13 e0207797 10.1371/journal.pone.0207797 30462732 PMC6249019 · DOI
  8. [9]Chua E.G. Verbrugghe P. Perkins T.T. Tay C.Y. Fucoidans Disrupt Adherence of Helicobacter pylori to AGS Cells In Vitro Evid. Complement. Altern. Med. eCAM 2015 2015 120981 10.1155/2015/120981 PMC4641203 26604968 · DOI
  9. [10]Besednova N.N. Zaporozhets T.S. Somova L.M. Kuznetsova T.A. Review: prospects for the use of extracts and polysaccharides from marine algae to prevent and treat the diseases caused by Helicobacter pylori Helicobacter 2015 20 89 97 10.1111/hel.12177 25660579 · DOI
  10. [11]Lin Y.H. Lu K.Y. Tseng C.L. Wu J.Y. Chen C.H. Mi F.L. Development of genipin-crosslinked fucoidan/chitosan-N-arginine nanogels for preventing Helicobacter infection Nanomedicine 2017 12 1491 1510 10.2217/nnm-2017-0055 28524785 · DOI
  11. [12]Oka S. Okabe M. Tsubura S. Mikami M. Imai A. Properties of fucoidans beneficial to oral healthcare Odontology 2019 10.1007/s10266-019-00437-3 31214896 · DOI
  12. [13]Park J. Cha J.D. Choi K.M. Lee K.Y. Han K.M. Jang Y.S. Fucoidan inhibits LPS-induced inflammation in vitro and during the acute response in vivo Int. Immunopharmacol. 2017 43 91 98 10.1016/j.intimp.2016.12.006 27987467 · DOI · Paper page
  13. [14]Hanisch F.G. Hansman G.S. Morozov V. Kunz C. Schroten H. Avidity of alpha-fucose on human milk oligosaccharides and blood group-unrelated oligo/polyfucoses is essential for potent norovirus-binding targets J. Biol. Chem. 2018 293 11955 11965 10.1074/jbc.RA117.001369 29858242 PMC6066315 · DOI
  14. [15]Sanjeewa K.K.A. Lee J.S. Kim W.S. Jeon Y.J. The potential of brown-algae polysaccharides for the development of anticancer agents: An update on anticancer effects reported for fucoidan and laminaran Carbohydr. Polym. 2017 177 451 459 10.1016/j.carbpol.2017.09.005 28962791 · DOI
  15. [16]Negishi H. Mori M. Mori H. Yamori Y. Supplementation of elderly Japanese men and women with fucoidan from seaweed increases immune responses to seasonal influenza vaccination J. Nutr. 2013 143 1794 1798 10.3945/jn.113.179036 24005608 PMC3796347 · DOI
  16. [17]Dutot M. Grassin-Delyle S. Salvator H. Brollo M. Rat P. Fagon R. Naline E. Devillier P. A marine-sourced fucoidan solution inhibits Toll-like-receptor-3-induced cytokine release by human bronchial epithelial cells Int. J. Biol. Macromol. 2019 130 429 436 10.1016/j.ijbiomac.2019.02.113 30797011 PMC7112488 · DOI
  17. [18]Klettner A. Fucoidan as a Potential Therapeutic for Major Blinding Diseases—A Hypothesis Mar. Drugs 2016 14 31 10.3390/md14020031 PMC4771984 26848666 · DOI
  18. [19]Dorschmann P. Bittkau K.S. Neupane S. Roider J. Alban S. Klettner A. Effects of Fucoidans from Five Different Brown Algae on Oxidative Stress and VEGF Interference in Ocular Cells Mar. Drugs 2019 17 258 10.3390/md17050258 PMC6562460 31052228 · DOI
  19. [20]Felisilda B.M.B. Alvarez de Eulate E. Stringer D.N. Fitton J.H. Arrigan D.W.M. Electrochemical behaviour at a liquid-organogel microinterface array of fucoidan extracted from algae Analyst 2017 142 3194 3202 10.1039/C7AN00761B 28758647 · DOI
  20. [21]Warttinger U. Giese C. Harenberg J. Holmer E. Krämer R. A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma Anal. Bioanal. Chem. 2016 408 8241 8251 10.1007/s00216-016-9940-y 27655335 · DOI
  21. [22]Espinosa-Velazquez G. Ramos-de-la-Pena A.M. Montanez J. Contreras-Esquivel J.C. Rapid physicochemical characterization of innovative fucoidan/fructan powders by ATR-FTIR Food Sci. Biotechnol. 2018 27 411 415 10.1007/s10068-017-0265-1 30263764 PMC6049647 · DOI
  22. [23]Zhu Z. Zhu B. Ai C. Lu J. Wu S. Liu Y. Wang L. Yang J. Song S. Liu X. Development and application of a HPLC-MS/MS method for quantitation of fucosylated chondroitin sulfate and fucoidan in sea cucumbers Carbohydr. Res. 2018 466 11 17 10.1016/j.carres.2018.07.001 29990587 · DOI
  23. [24]Fitton J.H. Stringer D.N. Karpiniec S.S. Park A.Y. The manufacture, characterization, and uses of fucoidans from macroalgae Enzymatic Technologies for Marine Polysaccharides CRC Press Boca Raton, FL, USA 2019 47 60
  24. [25]Pozharitskaya O.N. Shikov A.N. Faustova N.M. Obluchinskaya E.D. Kosman V.M. Vuorela H. Makarov V.G. Pharmacokinetic and Tissue Distribution of Fucoidan from Fucus vesiculosus after Oral Administration to Rats Mar. Drugs 2018 16 132 10.3390/md16040132 29669995 PMC5923419 · DOI
  25. [26]Tokita Y. Hirayama M. Nakajima K. Tamaki K. Iha M. Nagamine T. Detection of Fucoidan in Urine after Oral Intake of Traditional Japanese Seaweed, Okinawa mozuku (Cladosiphon okamuranus Tokida) J. Nutr. Sci. Vitaminol. 2017 63 419 421 10.3177/jnsv.63.419 29332904 · DOI
  26. [27]Tokita Y. Nakajima K. Mochida H. Iha M. Nagamine T. Development of a fucoidan-specific antibody and measurement of fucoidan in serum and urine by sandwich ELISA Biosci. Biotechnol. Biochem. 2010 74 350 357 10.1271/bbb.90705 20139614 · DOI
  27. [28]Zhao X. Guo F. Hu J. Zhang L. Xue C. Zhang Z. Li B. Antithrombotic activity of oral administered low molecular weight fucoidan from Laminaria Japonica Thromb. Res. 2016 144 46 52 10.1016/j.thromres.2016.03.008 27289072 · DOI
  28. [29]Zhang E. Chu F. Xu L. Liang H. Song S. Ji A. Use of fluorescein isothiocyanate isomer I to study the mechanism of intestinal absorption of fucoidan sulfate in vivo and in vitro Biopharm. Drug Dispos. 2018 39 298 307 10.1002/bdd.2137 29904925 · DOI
  29. [30]Masterson C.H. Curley G.F. Laffey J.G. Modulating the distribution and fate of exogenously delivered MSCs to enhance therapeutic potential: knowns and unknowns Intensive Care Med. Exp. 2019 7 41 10.1186/s40635-019-0235-4 31346794 PMC6658643 · DOI
  30. [31]Lee J.H. Yun C.W. Hur J. Lee S.H. Fucoidan Rescues p-Cresol-Induced Cellular Senescence in Mesenchymal Stem Cells via FAK-Akt-TWIST Axis Mar. Drugs 2018 16 121 10.3390/md16040121 PMC5923408 29642406 · DOI
  31. [32]Kan J. Hood M. Burns C. Scholten J. Chuang J. Tian F. Pan X. Du J. Gui M. A Novel Combination of Wheat Peptides and Fucoidan Attenuates Ethanol-Induced Gastric Mucosal Damage through Anti-Oxidant, Anti-Inflammatory, and Pro-Survival Mechanisms Nutrients 2017 9 978 10.3390/nu9090978 PMC5622738 28878183 · DOI
  32. [33]Kan J. Cheng J. Xu L. Hood M. Zhong D. Cheng M. Liu Y. Chen L. Du J. The combination of wheat peptides and fucoidan protects against chronic superficial gastritis and alters gut microbiota: a double-blinded, placebo-controlled study Eur. J. Nutr. 2019 10.1007/s00394-019-02020-6 31230147 · DOI
  33. [34]Takahashi H. Kawaguchi M. Kitamura K. Narumiya S. Kawamura M. Tengan I. Nishimoto S. Hanamure Y. Majima Y. Tsubura S. An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients Integr. Cancer Ther. 2018 17 282 291 10.1177/1534735417692097 28627320 PMC6041928 · DOI
  34. [36]Sakai C. Abe S. Kouzuki M. Shimohiro H. Ota Y. Sakinada H. Takeuchi T. Okura T. Kasagi T. Hanaki K. A Randomized Placebo-controlled Trial of an Oral Preparation of High Molecular Weight Fucoidan in Patients with Type 2 Diabetes with Evaluation of Taste Sensitivity Yonago Acta Med. 2019 62 14 23 10.33160/yam.2019.03.003 30962740 PMC6437402 · DOI
  35. [37]Wright C.M. Bezabhe W. Fitton J.H. Stringer D.N. Bereznicki L.R.E. Peterson G.M. Effect of a Fucoidan Extract on Insulin Resistance and Cardiometabolic Markers in Obese, Nondiabetic Subjects: A Randomized, Controlled Trial J. Altern. Complement. Med. 2019 25 346 352 10.1089/acm.2018.0189 30312135 · DOI
  36. [38]Tsubura S.S.A. Case report using 4% fucoidan cream for recurrent oral herpes labialis: Patient symptoms markedly improved in terms of time to healing and time to loss of discomfort Dent. Open, J. 2017 4 19 23 10.17140/DOJ-5-135 · DOI
  37. [39]Zayed A. Muffler K. Hahn T. Rupp S. Finkelmeier D. Burger-Kentischer A. Ulber R. Physicochemical and Biological Characterization of Fucoidan from Fucus vesiculosus Purified by Dye Affinity Chromatography Mar. Drugs 2016 14 79 10.3390/md14040079 PMC4849083 27092514 · DOI
  38. [40]Kadena K. Tomori M. Iha M. Nagamine T. Absorption Study of Mozuku Fucoidan in Japanese Volunteers Mar Drugs 2018 16 254 10.3390/md16080254 PMC6117716 30061499 · DOI
  39. [42]Li R. Boyd-Moss M. Long B. Martel A. Parnell A. Dennison A.J.C. Barrow C.J. Nisbet D.R. Williams R.J. Facile control over the supramolecular ordering of self-assembled peptide scaffolds by simultaneous assembly with a polysacharride Sci. Rep. 2017 7 4797 10.1038/s41598-017-04643-3 28684767 PMC5500548 · DOI
  40. [43]Maclean F.L. Wang Y. Walking R. Home M.K. Williams R.J. Nisbet D.R. Reducing astrocytic scarring after traumatic brain injury with a multifaceted anti-inflammatory hydrogel system ACS Biomater. Sci. Eng. 2017 3 2542 2549 10.1021/acsbiomaterials.7b00524 33465910 · DOI
  41. [44]Li R. Pavuluri S. Bruggeman K. Long B.M. Parnell A.J. Martel A. Parnell S.R. Pfeffer F.M. Dennison A.J.C. Nicholas K.R. Coassembled nanostructured bioscaffold reduces the expression of proinflammatory cytokines to induce apoptosis in epithelial cancer cells Nanomed. Nanotechnol. Biol. Med. 2016 10.1016/j.nano.2016.01.009 26961467 · DOI
  42. [45]Benbow N.L. Webber J.L. Karpiniec S. Krasowska M. Ferri J.K. Beattie D.A. The influence of polyanion molecular weight on polyelectrolyte multilayers at surfaces: protein adsorption and protein–polysaccharide complexation/stripping on natural polysaccharide films on solid supports Phys. Chem. Chem. Phys. 2017 19 23790 23801 10.1039/C7CP02599H 28664960 · DOI
  43. [46]Wang P. Kankala R.K. Chen B. Long R. Cai D. Liu Y. Wang S. Poly-allylamine hydrochloride and fucoidan-based self-assembled polyelectrolyte complex nanoparticles for cancer therapeutics J. Biomed. Mater. Res. A 2019 107 339 347 10.1002/jbm.a.36526 30548527 · DOI
  44. [47]Pawar V.K. Singh Y. Sharma K. Shrivastav A. Sharma A. Singh A. Meher J.G. Singh P. Raval K. Kumar A. Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin Int. J. Biol. Macromol. 2019 122 1100 1114 10.1016/j.ijbiomac.2018.09.059 30219515 · DOI
  45. [48]Manivasagan P. Hoang G. Santha Moorthy M. Mondal S. Minh Doan V.H. Kim H. Vy Phan T.T. Nguyen T.P. Oh J. Chitosan/fucoidan multilayer coating of gold nanorods as highly efficient near-infrared photothermal agents for cancer therapy Carbohydr. Polym. 2019 211 360 369 10.1016/j.carbpol.2019.01.010 30824100 · DOI
  46. [49]Shin S.W. Jung W. Choi C. Kim S.Y. Son A. Kim H. Lee N. Park H.C. Fucoidan-Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Co-Targeting Tumor Hypoxia and Angiogenesis Mar. Drugs 2018 16 510 10.3390/md16120510 PMC6316049 30558324 · DOI
  47. [50]Pajovich H.T. Banerjee I.A. Biomineralization of fucoidan-peptide blends and their potential applications in bone tissue regeneration J. Funct. Biomater. 2017 8 41 10.3390/jfb8030041 PMC5618292 29036882 · DOI
  48. [51]Ozaltin K. Lehocky M. Humpolicek P. Pelkova J. Saha P. A New Route of Fucoidan Immobilization on Low Density Polyethylene and Its Blood Compatibility and Anticoagulation Activity Int. J. Mol. Sci. 2016 17 908 10.3390/ijms17060908 PMC4926442 27294915 · DOI
  49. [52]Jeong Y. Thuy L.T. Ki S.H. Ko S. Kim S. Cho W.K. Choi J.S. Kang S.M. Multipurpose Antifouling Coating of Solid Surfaces with the Marine-Derived Polymer Fucoidan Macromol. Biosci. 2018 18 e1800137 10.1002/mabi.201800137 30113760 · DOI
  50. [53]Li B. Aid-Launais R. Labour M.N. Zenych A. Juenet M. Choqueux C. Ollivier V. Couture O. Letourneur D. Chauvierre C. Functionalized polymer microbubbles as new molecular ultrasound contrast agent to target P-selectin in thrombus Biomaterials 2019 194 139 150 10.1016/j.biomaterials.2018.12.023 30593939 · DOI
  51. [54]Li R. McRae N.L. McCulloch D.R. Boyd-Moss M. Barrow C.J. Nisbet D.R. Stupka N. Williams R.J. Large and Small Assembly: Combining Functional Macromolecules with Small Peptides to Control the Morphology of Skeletal Muscle Progenitor Cells Biomacromolecules 2018 19 825 837 10.1021/acs.biomac.7b01632 29389119 · DOI
  52. [55]Lee M.C. Huang Y.C. Soluble eggshell membrane protein-loaded chitosan/fucoidan nanoparticles for treatment of defective intestinal epithelial cells Int. J. Biol. Macromol. 2019 131 949 958 10.1016/j.ijbiomac.2019.03.113 30910672 · DOI
  53. [56]Goonoo N. Bhaw-Luximon A. Jonas U. Jhurry D. Schönherr H. Enhanced differentiation of human preosteoblasts on electrospun blend fiber mats of polydioxanone and anionic sulfated polysaccharides ACS Biomater. Sci. Eng. 2017 3 3447 3458 10.1021/acsbiomaterials.7b00350 29285521 PMC5739512 · DOI
  54. [57]Wang B. Adhikari B. Mathesh M. Yang W. Barrow C.J. Anchovy oil microcapsule powders prepared using two-step complex coacervation between gelatin and sodium hexametaphosphate followed by spray drying Powder Technol. 2018 10.1016/j.powtec.2018.07.034 · DOI
  55. [58]Chiang C.S. Lin Y.J. Lee R. Lai Y.H. Cheng H.W. Hsieh C.H. Shyu W.C. Chen S.Y. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy Nat. Nanotechnol. 2018 13 746 754 10.1038/s41565-018-0146-7 29760523 · DOI
  56. [59]Lu H.T. Chang W.T. Tsai M.L. Chen C.H. Chen W.Y. Mi F.L. Development of Injectable Fucoidan and Biological Macromolecules Hybrid Hydrogels for Intra-Articular Delivery of Platelet-Rich Plasma Mar. Drugs 2019 17 236 10.3390/md17040236 PMC6521258 31010247 · DOI
  57. [60]Ozaltin K. Lehocky M. Humpolicek P. Pelkova J. Di Martino A. Karakurt I. Saha P. Anticoagulant Polyethylene Terephthalate Surface by Plasma-Mediated Fucoidan Immobilization Polymers 2019 11 750 10.3390/polym11050750 PMC6572684 31035326 · DOI
  58. [61]Zheng Y. Wang T. Tu X. Huang Y. Zhang H. Tan D. Jiang W. Cai S. Zhao P. Song R. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma J. Immuno Ther. Cancer 2019 7 193 10.1186/s40425-019-0650-9 PMC6651993 31337439 · DOI · Paper page
  59. [62]Pryor R. Martinez-Martinez D. Quintaneiro L. Cabreiro F. The Role of the Microbiome in Drug Response Ann. Rev. Pharmacol. Toxicol. 2020 60 10.1146/annurev-pharmtox-010919-023612 31386593 · DOI
  60. [63]Mendez R. Kesh K. Arora N. Di Martino L. McAllister F. Merchant N. Banerjee S. Banerjee S. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer Carcinogenesis 2019 10.1093/carcin/bgz116 PMC7350554 31369062 · DOI
  61. [64]Tilg H. Zmora N. Adolph T.E. Elinav E. The intestinal microbiota fuelling metabolic inflammation Nat. Rev. Immunol. 2019 10.1038/s41577-019-0198-4 31388093 · DOI · Paper page
  62. [65]Iannone L.F. Preda A. Blottière H.M. Clarke G. Albani D. Belcastro V. Carotenuto M. Cattaneo A. Citraro R. Ferraris C. Microbiota-gut brain axis involvement in neuropsychiatric disorders Expert Rev. Neurother. 2019 1 14 10.1080/14737175.2019.1638763 31260640 · DOI · Paper page
  63. [66]Shang Q. Shan X. Cai C. Hao J. Li G. Yu G. Dietary fucoidan modulates the gut microbiota in mice by increasing the abundance of Lactobacillus and Ruminococcaceae Food Funct. 2016 7 3224 3232 10.1039/C6FO00309E 27334000 · DOI
  64. [67]Teruya K. Kusumoto Y. Eto H. Nakamichi N. Shirahata S. Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract Mar. Drugs 2019 17 421 10.3390/md17070421 31331053 PMC6669552 · DOI
  65. [68]Xue M. Ji X. Liang H. Liu Y. Wang B. Sun L. Li W. The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer Food Funct. 2018 9 1214 1223 10.1039/C7FO01677H 29384543 · DOI
  66. [70]Kan J. Du J. The Combination of Wheat Peptides and Fucoidan Protects Against Chronic Superficial Gastritis and Regulates Gut Microbiota: A Double-blinded, Placebo-controlled Study (P06-104-19) Curr. Dev. Nutr. 2019 3 10.1093/cdn/nzz031.P06-104-19 31230147 · DOI
  67. [71]Kosono S. Kasai A. Komaba S. Matsubara T. Sato T. Takahashi D. Toshima K. Novel hemagglutinin-binding sulfated oligofucosides and their effect on influenza virus infection Chem. Commun. 2018 54 7467 7470 10.1039/C8CC03865A 29915822 · DOI
  68. [72]Wang W. Wu J. Zhang X. Hao C. Zhao X. Jiao G. Shan X. Tai W. Yu G. Inhibition of Influenza A Virus Infection by Fucoidan Targeting Viral Neuraminidase and Cellular EGFR Pathway Sci. Rep. 2017 7 40760 10.1038/srep40760 28094330 PMC5240104 · DOI
  69. [73]Huang T.H. Chiu Y.H. Chan Y.L. Chiu Y.H. Wang H. Huang K.C. Li T.L. Hsu K.H. Wu C.J. Prophylactic Administration of Fucoidan Represses Cancer Metastasis by Inhibiting Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinases (MMPs) in Lewis Tumor-Bearing Mice Mar. Drugs 2015 13 1882 1900 10.3390/md13041882 25854641 PMC4413192 · DOI
  70. [74]Bobinski M. Okla K. Bednarek W. Wawruszak A. Dmoszynska-Graniczka M. Garcia-Sanz P. Wertel I. Kotarski J. The Effect of Fucoidan, a Potential New, Natural, Anti-Neoplastic Agent on Uterine Sarcomas and Carcinosarcoma Cell Lines: ENITEC Collaborative Study Arch. Immunol. Ther. Exp. 2019 67 125 131 10.1007/s00005-019-00534-9 30659312 PMC6420609 · DOI
  71. [75]Lee J. Lee S. Synytsya A. Capek P. Lee C.W. Choi J.W. Cho S. Kim W.J. Park Y.I. Low Molecular Weight Mannogalactofucans Derived from Undaria pinnatifida Induce Apoptotic Death of Human Prostate Cancer Cells In Vitro and In Vivo Mar. Biotechnol. 2018 20 813 828 10.1007/s10126-018-9851-3 30159630 · DOI
  72. [76]Blaszczak W. Lach M.S. Barczak W. Suchorska W.M. Fucoidan Exerts Anticancer Effects Against Head and Neck Squamous Cell Carcinoma In Vitro Molecules 2018 23 302 10.3390/molecules23123302 30545161 PMC6321539 · DOI
  73. [77]Mathew L.B.M. Gaikwad A. Nyshadham P. Nugent E.K. Gonzalez A. Smith J.A. Preclinical Evaluation of Safety of Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus for Use in Cancer Treatment Integr. Cancer Ther. 2016 1-13 10.1177/1534735416680744 PMC5739145 29096568 · DOI
  74. [78]Dithmer M. Kirsch A.M. Richert E. Fuchs S. Wang F. Schmidt H. Coupland S.E. Roider J. Klettner A. Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines Mar. Drugs 2017 15 193 10.3390/md15070193 28640204 PMC5532635 · DOI
  75. [80]Corban M. Ambrose M. Pagnon J. Stringer D. Karpiniec S. Park A. Eri R. Fitton J.H. Gueven N. Pathway Analysis of Fucoidan Activity Using a Yeast Gene Deletion Library Screen Mar. Drugs 2019 17 54 10.3390/md17010054 30646537 PMC6356313 · DOI
  76. [81]Malyarenko O.S. Zdobnova E.V. Silchenko A.S. Kusaykin M.I. Ermakova S.P. Radiosensitizing effect of the fucoidan from brown alga Fucus evanescens and its derivative in human cancer cells Carbohydr. Polym. 2019 205 465 471 10.1016/j.carbpol.2018.10.083 30446129 · DOI
  77. [82]Yu H.H. Chengchuan Ko E. Chang C.L. Yuan K.S. Wu A.T.H. Shan Y.S. Wu S.Y. Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues Mar. Drugs 2018 16 392 10.3390/md16100392 PMC6213111 30347679 · DOI
  78. [83]Irhimeh M.R. Fitton J.H. Lowenthal R.M. Fucoidan ingestion increases the expression of CXCR4 on human CD34+ cells Exp. Hematol. 2007 35 989 994 10.1016/j.exphem.2007.02.009 17533053 · DOI
  79. [84]Anisimova N.Y. Ustyuzhanina N.E. Bilan M.I. Donenko F.V. Ushakova N.A. Usov A.I. Kiselevskiy M.V. Nifantiev N.E. Influence of Modified Fucoidan and Related Sulfated Oligosaccharides on Hematopoiesis in Cyclophosphamide-Induced Mice Mar. Drugs 2018 16 333 10.3390/md16090333 30216993 PMC6164909 · DOI
  80. [85]Burney M. Mathew L. Gaikwad A. Nugent E.K. Gonzalez A.O. Smith J.A. Evaluation Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus in Combination With Anticancer Drugs in Human Cancer Orthotopic Mouse Models Integr. Cancer Ther. 2018 17 755 761 10.1177/1534735417740631 29156992 PMC6142089 · DOI
  81. [86]Bonnard T. Yang G. Petiet A. Ollivier V. Haddad O. Arnaud D. Louedec L. Bachelet-Violette L. Derkaoui S.M. Letourneur D. Abdominal aortic aneurysms targeted by functionalized polysaccharide microparticles: A new tool for SPECT imaging Theranostics 2014 4 592 603 10.7150/thno.7757 24723981 PMC3982130 · DOI
  82. [87]Vigne J. Cognet T. Guedj K. Morvan M. Merceron O. Louedec L. Choqueux C. Nicoletti A. Escoubet B. Chaubet F. Early Detection of Localized Immunity in Experimental Autoimmune Myocarditis Using [(99m)Tc]Fucoidan SPECT Mol. Imaging Biol. 2019 10.1007/s11307-019-01420-8 31432389 · DOI
  83. [88]Juenet M. Aid-Launais R. Li B. Berger A. Aerts J. Ollivier V. Nicoletti A. Letourneur D. Chauvierre C. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin Biomaterials 2018 156 204 216 10.1016/j.biomaterials.2017.11.047 29216534 · DOI
  84. [89]Choi Y. Min S.K. Usoltseva R. Silchenko A. Zvyagintseva T. Ermakova S. Kim J.K. Thrombolytic fucoidans inhibit the tPA-PAI1 complex, indicating activation of plasma tissue-type plasminogen activator is a mechanism of fucoidan-mediated thrombolysis in a mouse thrombosis model Thromb. Res. 2018 161 22 25 10.1016/j.thromres.2017.11.015 29178986 · DOI
  85. [90]Abdollah M.R.A. Carter T.J. Jones C. Kalber T.L. Rajkumar V. Tolner B. Gruettner C. Zaw-Thin M. Baguna Torres J. Ellis M. Fucoidan Prolongs the Circulation Time of Dextran-Coated Iron Oxide Nanoparticles ACS Nano 2018 10.1021/acsnano.7b06734 29341587 · DOI
  86. [91]Lahrsen E. Schoenfeld A.K. Alban S. Size-dependent pharmacological activities of differently degraded fucoidan fractions from Fucus vesiculosus Carbohydr. Polym. 2018 189 162 168 10.1016/j.carbpol.2018.02.035 29580394 · DOI
  87. [92]Lahrsen E. Liewert I. Alban S. Gradual degradation of fucoidan from Fucus vesiculosus and its effect on structure, antioxidant and antiproliferative activities Carbohydr. Polym. 2018 192 208 216 10.1016/j.carbpol.2018.03.056 29691015 · DOI
  88. [93]Kim H. Ahn J.H. Song M. Kim D.W. Lee T.K. Lee J.C. Kim Y.M. Kim J.D. Cho J.H. Hwang I.K. Pretreated fucoidan confers neuroprotection against transient global cerebral ischemic injury in the gerbil hippocampal CA1 area via reducing of glial cell activation and oxidative stress Biomed. Pharmacother. 2019 109 1718 1727 10.1016/j.biopha.2018.11.015 30551426 · DOI
  89. [94]Alghazwi M. Smid S. Karpiniec S. Zhang W. Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida Int. J. Biol. Macromol. 2019 122 255 264 10.1016/j.ijbiomac.2018.10.168 30401646 · DOI
  90. [95]Liang Z. Liu Z. Sun X. Tao M. Xiao X. Yu G. Wang X. The Effect of Fucoidan on Cellular Oxidative Stress and the CatD-Bax Signaling Axis in MN9D Cells Damaged by 1-Methyl-4-Phenypyridinium Front. Aging Neurosci. 2018 10 429 10.3389/fnagi.2018.00429 30700973 PMC6343539 · DOI
  91. [96]Meenakshi S. Umayaparvathi S. Saravanan R. Manivasagam T. Balasubramanian T. Neuroprotective effect of fucoidan from Turbinaria decurrens in MPTP intoxicated Parkinsonic mice Int. J. Biol. Macromol. 2016 86 425 433 10.1016/j.ijbiomac.2015.12.025 26828289 · DOI
  92. [97]Bell J.S. Spencer J.I. Yates R.L. Yee S.A. Jacobs B.M. DeLuca G.C. Invited Review: From nose to gut - the role of the microbiome in neurological disease Neuropathol. Appl. Neurobiol. 2019 45 195 215 10.1111/nan.12520 30298527 · DOI
  93. [98]Zhang L. Hao J. Zheng Y. Su R. Liao Y. Gong X. Liu L. Wang X. Fucoidan Protects Dopaminergic Neurons by Enhancing the Mitochondrial Function in a Rotenone-induced Rat Model of Parkinson’s Disease Aging Dis. 2018 9 590 604 10.14336/AD.2017.0831 30090649 PMC6065300 · DOI

Authors
Fitton, J. H., Stringer, D. N., Park, A. Y., & Karpiniec, S. S.
Affiliations
Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia
Corresponding author
Fitton, J. Helen
ORCID
Venue
Marine Drugs
Publisher
MDPI AG
Published
2019-10-09
Volume
17
Issue
10
Pages
571
ISSN
1660-3397 (ISSN-L)
DOI
10.3390/md17100571
PMC
PMC6836154
OpenAlex
W2979361360
Cited by
225
References
98
Citations by year
2026: 37 · 2025: 25 · 2024: 45 · 2023: 37 · 2022: 29 · 2021: 23 · 2020: 27 · 2019: 1 · 2016: 1
FWCI
1.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Marine Drugs (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Seaweed-derived Bioactive Compounds
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Echinoderm biology and ecology
  • Health Sciences › Medicine › Pharmacology › Fungal Biology and Applications
Keywords
fucoidan, kidney disease, thrombus imaging, dietary supplements, topical treatment, microbiota modulation, marine polysaccharides
MeSH terms
Animals, Humans, Polysaccharides, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review